September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The uPAR/FPR antagonist UPARANT shows anti-angiogenic and antinflammatory properties in rodent models of retinal neovascular diseases.
Author Affiliations & Notes
  • Dario Rusciano
    Sooft Spa, Roma, Italy
  • Paola Bagnoli
    University, Pisa, Italy
  • Helder André
    Karolinska, Stockholm, Sweden
  • Massimo Dal Monte
    University, Pisa, Italy
  • Maurizio Cammalleri
    University, Pisa, Italy
  • Filippo Locri
    University, Pisa, Italy
  • Monica Aronsson
    Karolinska, Stockholm, Sweden
  • Anders P Kvanta
    Karolinska, Stockholm, Sweden
  • Liliana Lista
    University, Pisa, Italy
  • Vincenzo Pavone
    University, Pisa, Italy
  • Mario De Rosa
    University, Pisa, Italy
  • Footnotes
    Commercial Relationships   Dario Rusciano, Sooft Italia SpA (E); Paola Bagnoli, Bioos srl (F); Helder André, None; Massimo Dal Monte, None; Maurizio Cammalleri, None; Filippo Locri, None; Monica Aronsson, None; Anders Kvanta, None; Liliana Lista, None; Vincenzo Pavone, Pharmafelix (I); Mario De Rosa, Pharmafelix (I)
  • Footnotes
    Support  Grant from the European Community and the Italian Ministry for University and Research (MIUR): PON 01_02464
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1114. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dario Rusciano, Paola Bagnoli, Helder André, Massimo Dal Monte, Maurizio Cammalleri, Filippo Locri, Monica Aronsson, Anders P Kvanta, Liliana Lista, Vincenzo Pavone, Mario De Rosa; The uPAR/FPR antagonist UPARANT shows anti-angiogenic and antinflammatory properties in rodent models of retinal neovascular diseases.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1114.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Treatment of retinal neovascular diseases by anti-VEGF based therapies has two major flaws: one third of patients respond poorly, and chronic depletion of VEGF may have neurotoxic effects. We investigated in experimental rodent models of neovascular diseases the anti-angiogenic effects of a new synthetic molecule (UPARANT) designed to inhibit endothelial cells response to a wide variety of angiogenic triggers.

Methods : Lesions in the choroid (CNV) were induced by laser treatment in 6- to 8-week-old C57Bl6J mice (N = 54). At day 4, 8 and 12 after CNV induction, animals were treated with intravitreal injections of UPARANT at 4 and 12 mg in 1 ml, and euthanized at day 15 for analyses. Diabetes was induced in 8-week-old Sprague-Dawley rats (N=20) by a streptozotocin intraperitoneal injection. UPARANT (40 mg in 4 ml) was given by weekly intravitreal injections between weeks 6 and 9 after diabetes induction. Animals were euthanized at week 10 for analyses. Oxidative retinopathy was induced between postnatal day (P) 7 and 12 in C57Bl/6 newborn mice (N = 12) that were then treated by intravitreal injections of 15ng in 1ml UPARANT, 2 µg/ml aflibercept and 1.25 µg/ml bevacizumab at P 12 and 15. At P 17 animals were euthanized for analyses. All control animals were treated with vehicle alone. Student’s t test for unpaired data, or ANOVA with Newman-Keuls post-hoc test correction were used to evaluate the data.

Results : UPARANT reduced CNV area in a dose-dependent manner. UPARANT at 4 mg and 12 mg progressively reduced the CNV area by about 40 % (P < 0.01) and 60% (P < 0.001). UPARANT also recovered the laser-induced up-regulation of transcription factors controlling genes involved in angiogenesis and inflammation. Accordingly, gene expression of angiogenic and inflammatory markers was also significantly reduced. UPARANT strongly decreased retinal neoangiogenesis in diabetic rats, normalizing the blood retinal barrier and recovering the ERG. In the OIR model, UPARANT normalized the blood retinal barrier more efficiently than aflibercept or bevacizumab.

Conclusions : Our data clearly show that inhibition of the uPAR/FPR interaction at the cell surface by UPARANT is able to ameliorate neovascular pathologies in the eye most likely by controlling the production of angiogenic and inflammatory factors, thus restoring a close-to-normal barrier and retinal function.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.